- Home
- DYAI vs LSTA Comparison
DYAI vs LSTA Comparison
Compare DYAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | LSTA |
|---|---|---|
| Founded | 1979 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 15.9M |
| IPO Year | 2026 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DYAI | LSTA |
|---|---|---|
| Price | $0.33 | $1.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 91.2K | ★ 108.7K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $3,090,345.00 | ★ $35,283,868.00 |
| Revenue This Year | $113.16 | N/A |
| Revenue Next Year | $94.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.33 | $0.96 |
| 52 Week High | $1.60 | $5.07 |
Technical Indicators
Market Signals| Indicator | DYAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 56.44 |
| Support Level | N/A | $1.23 |
| Resistance Level | $0.48 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 8.59 | 56.18 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.